Written by/reviewed by: Kristi Monson, PharmD; Arthur Schoenstadt, MD
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Prevacid [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.;2012 May.
Food and Drug Administration. FDA drug safety communication; low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs) (3/2/11). FDA Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm. Accessed March 17, 2011.
Clinical Pharmacology [database online]. Drug Interaction Report. Tampa, FL: Gold Standard, Inc.; 2010. Available at: http://www.clinicalpharmacology.com. Accessed March 17, 2011.
Prevacid 24HR [OTC package label]. Novartis Consumer Health, Inc.
Food and Drug Administration, Center for Drug Evaluation and Research. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors (5/25/2010). FDA Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm. Accessed May 28, 2010.